Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Logic Adds Lilly To Its Drug Rescue Roster

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.

You may also be interested in...



Abbott Joins Gene Logic’s Stable Of Pharma Partners

Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.

Abbott Joins Gene Logic’s Stable Of Pharma Partners

Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.

Pfizer Aims To Revive Drug Candidates Through Gene Logic Agreement

Gene Logic will screen unapproved compounds for possible new indications with the goal of returning them to clinical development.

Related Content

Topics

UsernamePublicRestriction

Register

PS063179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel